Therapeutic approaches to vascular Ehlers–Danlos syndrome

Potential therapeutic approaches to vascular Ehlers–Danlos syndrome. Celiprolol may reduce total peripheral resistance by dilating skeletal muscle resistance vessels through β2-adrenergic receptors and might decrease arterial wall shear stress by lowering heart rate through β1-adrenergic receptor antagonism. This drug could also reduce vascular oxidative stress at the arterial wall level by stimulating nitric oxide production. Lastly, it might increase arterial stiffness by enhancing TGFβ-mediated pro-fibrotic mechanisms and promoting collagen synthesis via β1 antagonism and β2 stimulation, respectively. By acting on angiotensin receptors, sartans could provide vascular protection either by inducing vasodilation or by limiting the adverse effects of angiotensin II on vascular remodeling. Targeting matrix metalloproteinases (MMPs) via doxycycline might counteract collagen degradation, thereby increasing its content in the arterial wall and enhancing vessel stiffness. Inhibition of phospholipase C/inositol 1,4,5-triphosphate/protein kinase C/extracellular signal-regulated kinase (PLC/IP3/PKC/ERK) has been shown to prevent spontaneous fatal aortic rupture in a mouse model. Antiandrogen medications may also contribute by interfering with this signaling pathway. Future research should identify drugs capable of improving mechanisms of autophagy, endoplasmic reticulum (ER) homeostasis, and stress response, which are likely to contribute substantially in the natural history of vEDS. Red lines: inhibition; green lines: stimulation; AR: androgen receptor; AT1R: angiotensin 1 receptor; β2AR: β2-adrenergic receptor; DHT: dihydrotestosterone; ECM: extracellular matrix; ER: endoplasmic reticulum; MMP: matrix metalloproteinase
Therapeutic approaches to vascular Ehlers–Danlos syndrome

Publication

Current Evidence and Future Perspectives in the Medical Management of Vascular Ehlers–Danlos Syndrome: Focus on Vascular Prevention (2024) Giacomo Buso, et al. J Clin Med. 2024 Jul;13(14). Figure: F1.

Gene mentions


Organism Group Word Match Source NCBI Symbol NCBI ID
Homo sapiens Primates B2AR B2AR ncbigene_synonym ADRB2 154
Homo sapiens Primates MMP9 MMP9 ncbigene_symbol MMP9 4318
Homo sapiens Primates ATR ATR ncbigene_symbol ATR 545
Homo sapiens Primates ATR ATR ncbigene_synonym ANTXR1 84168
Homo sapiens Primates ATR ATR ncbigene_synonym MMAB 326625
Homo sapiens Primates ATR ATR ncbigene_synonym SERPINA2 390502
Homo sapiens Primates Gq/11 GQ famplex_relations GNAQ 2776
Homo sapiens Primates Gq/11 GQ famplex_relations GNA11 2767
Homo sapiens Primates Gq/11 GQ famplex_relations GNA14 9630
Homo sapiens Primates Gq/11 GQ famplex_relations GNA15 2769
Homo sapiens Primates Src SRC ncbigene_symbol SRC 6714
Homo sapiens Primates Src SRC famplex_relations FGR 2268
Homo sapiens Primates Src SRC famplex_relations FYN 2534
Homo sapiens Primates Src SRC famplex_relations YES1 7525
Homo sapiens Primates PLC PLC ncbigene_synonym HSPG2 3339
Homo sapiens Primates PLC PLC famplex_relations PLCE1 51196
Homo sapiens Primates PLC PLC famplex_relations PLCZ1 89869
Homo sapiens Primates PLC PLC famplex_relations PLCB1 23236
Homo sapiens Primates PLC PLC famplex_relations PLCB2 5330
Homo sapiens Primates PLC PLC famplex_relations PLCB3 5331
Homo sapiens Primates PLC PLC famplex_relations PLCB4 5332
Homo sapiens Primates PLC PLC famplex_relations PLCD1 5333
Homo sapiens Primates PLC PLC famplex_relations PLCD3 113026
Homo sapiens Primates PLC PLC famplex_relations PLCD4 84812
Homo sapiens Primates PLC PLC famplex_relations PLCG1 5335
Homo sapiens Primates PLC PLC famplex_relations PLCG2 5336
Homo sapiens Primates PKC PKC ncbigene_synonym PRRT2 112476
Homo sapiens Primates PKC PKC famplex_relations PRKCA 5578
Homo sapiens Primates PKC PKC famplex_relations PRKCB 5579
Homo sapiens Primates PKC PKC famplex_relations PRKCD 5580
Homo sapiens Primates PKC PKC famplex_relations PRKCE 5581
Homo sapiens Primates PKC PKC famplex_relations PRKCG 5582
Homo sapiens Primates PKC PKC famplex_relations PRKCH 5583
Homo sapiens Primates PKC PKC famplex_relations PRKCI 5584
Homo sapiens Primates PKC PKC famplex_relations PRKCQ 5588
Homo sapiens Primates PKC PKC famplex_relations PRKCZ 5590
Homo sapiens Primates PKC PKC famplex_relations PRKD3 23683
Homo sapiens Primates AR AR ncbigene_symbol AR 367
Homo sapiens Primates MEK MEK ncbigene_synonym MAP2K7 5609
Homo sapiens Primates MEK MEK famplex_relations MAP2K1 5604
Homo sapiens Primates MEK MEK famplex_relations MAP2K2 5605
Homo sapiens Primates PKA PKA famplex_relations PRKAR1A 5573
Homo sapiens Primates PKA PKA famplex_relations PRKAR1B 5575
Homo sapiens Primates PKA PKA famplex_relations PRKAR2A 5576
Homo sapiens Primates PKA PKA famplex_relations PRKAR2B 5577
Homo sapiens Primates PKA PKA famplex_relations PRKACA 5566
Homo sapiens Primates PKA PKA famplex_relations PRKACB 5567
Homo sapiens Primates PKA PKA famplex_relations PRKACG 5568
Homo sapiens Primates ERK ERK ncbigene_synonym EPHB2 2048
Homo sapiens Primates ERK ERK ncbigene_synonym MAPK1 5594
Homo sapiens Primates ERK ERK famplex_relations MAPK3 5595
Homo sapiens Primates large LARGE ncbigene_synonym LARGE1 9215

Chemical mentions

Word Match MeSH Name ChEBI
Doxycycline doxycycline (4S,4aR,5S,5aR,6R,12aS)-4-(dimethylamino)-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide--water (1/1) chebi:60648
Losartan losartan 5-(4'-{[2-butyl-4-chloro-5-(hydroxymethyl)-1H-imidazol-1-yl]methyl}[biphenyl]-2-yl)tetrazol-1-ide chebi:149504
Irbesartan irbesartan 2-butyl-3-{[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl}-1,3-diazaspiro[4.4]non-1-en-4-one chebi:5959
DHT DHT 17beta-hydroxy-5alpha-androstan-3-one chebi:16330
Adenylate Adenylate 5'-adenylic acid chebi:16027
Hydralazine hydralazine 1-hydrazinophthalazine chebi:5775
CAMP cAMP adenosine 3',5'-(hydrogen phosphate) chebi:17489
MEK MEK butan-2-one chebi:28398
Spironolactone spironolactone 7alpha-(acetylsulfanyl)-3-oxo-17alpha-pregn-4-ene-21,17-carbolactone chebi:9241
Bicalutamide bicalutamide rac-N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide chebi:3090
Cobimetinib cobimetinib bis[(2S)-2-{1-[3,4-difluoro-2-(2-fluoro-4-iodoanilino)benzoyl]-3-hydroxyazetidin-3-yl}piperidin-1-ium] (2E)-but-2-enedioate chebi:90853

Disease mentions

Word Match MeSH Name DOID